News • Oncology

Biodegradable hydrogel boosts immune system’s attack on cancers

A new biodegradable gel improves the immune system’s ability to keep cancer at bay after tumors are surgically removed. The gel, tested in mice, releases drugs and special antibodies that simultaneously deplete immune-blocking cells called macrophages from the surgical site and activate T cells so they can attack cancer.

Photo
A high-magnification of the hydrogel (in blue) encapsulating T cell-activating platelets (in red) and nanoparticles that release a drug to inhibit tumor-boosting cells (in green). This gel inhibited the growth of cancer cells after surgical removal of different types of tumors.
Source: UW–Madison

University of Wisconsin–Madison scientists tested the gel on mouse models of several cancers. They found that the gel effectively kept in check tumors that are known to respond well to this kind of immune therapy, like CT26 colon cancers. But the gel also worked well against B16F10 melanomas, S180 sarcomas and 4T1 triple negative breast cancers, which are less responsive to immune therapy and more prone to metastasizing.

These proof-of-concept experiments will support additional research on other animal models that could lead to future clinical trials in people.

The experiments were led by the lab of Quanyin Hu, a professor in the UW–Madison School of Pharmacy, with support from pharmacy professor Seungpyo Hong and colleagues in the UW School of Medicine and Public Health. “We are really glad to see that this local strategy can work against so many different kinds of tumors, especially these non-immunogenic tumors,” says Hu. “We are even more glad to see this local treatment can inhibit tumor metastasis.”

Surgery is an excellent treatment for many tumors, but small numbers of cancer cells that remain after the operation can allow tumors to grow back. To counteract this process, the researchers developed their gel to slowly release into the surgical site two key components.

One is the drug Pexidartinib, which is approved for use to inhibit the function of tumor-associated macrophages. These cells promote the growth of tumors, and inhibiting the cells slows that cancerous growth. The second component of the gel were platelets — the bits of cells that clot blood — bound to immune-stimulating antibodies. These antibodies, known as anti-PD-1, help the immune system’s T cells recognize and attack cancerous cells.

The researchers hoped that the local release of the antibody-bound platelets and Pexidartinib would both maximize their effect near the tumor site and minimize side effects that occur when these therapies are given intravenously and circulate widely in the body. Indeed, mice given the gel showed insignificant side effects. Bodies degrade the gel over time.

Hu’s team tested the gel against a broad suite of cancers because these tumors vary in how they respond to immune-based therapies like the anti-PD-1-conjugated platelets. In each case, the gel significantly slowed the growth of lingering cancer cells and increased the lifespan of mice. The gel also greatly reduced the spread of the metastasizing breast cancer model the researchers examined.

In recent years, Hong and Hu have independently been developing new ways to control cancers without traditional chemotherapy, which has severe side effects. Now collaborating, they plan to continue testing creative approaches that could find their way into human patients in the coming years.

“This is just the initial phase of collaboration between our two labs,” says Hong.

Source: University of Wisconsin–Madison

08.04.2022

Read all latest stories

Related articles

Photo

News • Histotripsy

Tumors partially destroyed with ultrasound don't come back

Noninvasive sound technology breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread.

Photo

News • Cancer 'avatars'

Predicting immunotherapy outcomes with mini tumours

Miniature tumours in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing:…

Photo

News • Immunotherapy response prediction

Pulling the "molecular brake" on tumor cells

An unexpected discovery that could bring new hope to cancer patients worldwide: Researchers from the University of California San Diego have identified a mechanism that could predict response to…

Related products

Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
Subscribe to Newsletter